Starpharma Holdings LtdShs Aktie
| 0,06EUR | 0,00EUR | -4,00% |
WKN: 796461 / ISIN: AU000000SPL0
Personal
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 50 | 50 | 45 | 40 | 40 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0,04 | 0,09 | 0,07 | 0,21 | 0,12 |
Bilanz (in Mio. AUD) - Aktiva
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 71 | 61 | 47 | 33 | 23 |
| Summe Anlagevermögen | 2 | 6 | 5 | 4 | 3 |
| Summe Aktiva | 73 | 66 | 52 | 37 | 25 |
Bilanz (in Mio. AUD) - Passiva
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Summe Fremdkapital | 11 | 18 | 17 | 9 | 6 |
| Summe Eigenkapital | 62 | 48 | 35 | 28 | 19 |
| Summe Passiva | 73 | 66 | 52 | 37 | 25 |
Adresse
| 4-6 Southampton Crescent, 3067 Abbotsford | |
| Telefon | +61 (3) 8532-2700 |
| Internet | http://www.starpharma.com |
Management
|
Cheryl Maley
Chief Executive Officer, Director & MD |
|
David John McIntyre
Independent Non-Executive Director |
|
Jeff Davies
Independent Non-Executive Director |
|
Jeremy R. Paull
Vice President-Development & Regulatory Affairs |
|
Justin Cahill
Chief Financial Officer & Secretary |
|
Lynda Cheng
Independent Non-Executive Director |
|
Miranda Sowden
Director-People & Culture |
|
Robert Bain Thomas
Chairman |
|
Russell Basser
Independent Non-Executive Director |
|
Tony Eglezos
Vice President-Business Development |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.